HCW Biologics is trading at $2.67 (6.8% up) as shares recover from last week’s steep decline, bolstered by renewed investor focus on its regulatory pipeline.
- The company recently disclosed it has requested a meeting with the FDA to discuss the advancement of its preclinical cancer drug program.
- While the asset is still in the early stages of development, the potential for clinical progress has sparked speculative interest in the micro-cap biotech firm.
- Today's gains represent a significant bounce-back following a period of heavy selling pressure in previous sessions.